Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
, 99 (4), e19011

Preliminary Study on the Clinical Significance of Kinesin Kif18a in Nonsmall Cell Lung Cancer: An Analysis of 100 Cases

Affiliations
Observational Study

Preliminary Study on the Clinical Significance of Kinesin Kif18a in Nonsmall Cell Lung Cancer: An Analysis of 100 Cases

Weifeng Guo et al. Medicine (Baltimore).

Abstract

The aim of this study was to investigate the expression of Kif18A in cancerous and paracancerous tissues from 100 patients with nonsmall cell lung cancer (NSCLC).This was a prospective study of 100 patients with pathologically confirmed NSCLC (adenocarcinoma and squamous cell carcinoma [SCC], n = 50/group) that were operated at the Quanzhou First Hospital Affiliated to Fujian Medical University between June 2015 and December 2016. Kif18A protein expression in cancerous and paracancerous normal tissues was detected by western blot and immunohistochemistry.The expression of the Kif18A protein was higher in adenocarcinoma and SCC tissues than in the corresponding paracancerous normal tissues. The expression of the Kif18A protein was higher in highly differentiated tumors, in patients with lymph node metastasis (vs no lymph node metastasis), adenocarcinoma, and in stage III NSCLC. There were no associations between Kif18A expression and age, gender, and pathologic type.The expression of the Kif18A protein by immunohistochemistry was higher in NSCLC tissues than in normal tissues, and was associated with tumor differentiation, lymph node metastasis, and TNM staging. These results could provide a theoretical basis for novel molecular targeted therapies against NSCLC.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Patient flowchart.
Figure 2
Figure 2
Expression of Kif18A protein by western blot in (A) lung adenocarcinoma (ADC) and (B) lung squamous cell carcinoma (SCC). The top panels present representative western blots. The bottom panel represents the average values from different samples. P < .05 vs paracancerous normal (PN) tissues.
Figure 3
Figure 3
Expression of Kif18A protein by immunohistochemistry in (A) lung adenocarcinoma (ADC) (40×) and (B) lung squamous cell carcinoma (SCC) (40×). The top panels present representative immunohistochemistry images. The bottom panel represents the average values from different samples. P < .05 vs paracancerous normal (PN) tissues.

Similar articles

See all similar articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29. - PubMed
    1. She J, Yang P, Hong Q, et al. Lung cancer in China: challenges and interventions. Chest 2013;143:1117–26. - PubMed
    1. Carney DN. Lung cancer--time to move on from chemotherapy. N Engl J Med 2002;346:126–8. - PubMed
    1. Ries LAG, Young JL, Keel GE, et al. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215. Bethesda: National Cancer Institute; 2007.
    1. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794–801. - PubMed

Publication types

Feedback